phosphocreatine
Small moleculeexperimental
Phosphocreatine, also known as creatine phosphate (CP) or PCr (Pcr), is a phosphorylated form of creatine that serves as a rapidly mobilizable reserve of high-energy phosphates in skeletal muscle, myocardium and the brain to recycle adenosine triphosphate (ATP), the energy currency of the cell. — Wikipedia
Clinical trial activity
4 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
4
Phase 3
2
Phase 4
0
Earliest trial started Jun 1, 2016 (NCT02757443)
Timeline
Indications
Studied for
- Airway Management · Phase 3
- Bradycardia · Phase 3
- Cardiac Surgical Procedures · Phase 3
- Consciousness Disorders · Phase 3
- Depression · Phase 2
- Heart Arrest · Phase 3
- Heart Failure · Phase 3
- Heart Valve Prosthesis Implantation · Phase 3
- Hypotension · Phase 3
- Major Depressive Disorder · Phase 2
- Respiration · Phase 3
- Respiratory Insufficiency · Phase 3
- Tachycardia · Phase 3
- Tachypnea · Phase 3
Mechanism of action
- Unspecified targetSupplementation
supplementation
Chemistry & pharmacology
Loading structure…
SMILES
CN(CC(=O)O)C(=N)NP(=O)(O)O- Mol. weight
- 211.11 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaPhosphocreatine ↗
- ChEMBLCHEMBL1204644 ↗
Also known as
- creatine-p
- creatine-p
- creatine phosphate
- creatine phosphate
- creatine phosphic acid
- creatine phosphic acid
- fosfocreatine
- fosfocreatine
- fosfocreatine
- fosfocreatine
- neoton
- n-(n-phosphonoamido)sarcosine
- n-(n-phosphonoamido)sarcosine
- n-phosphocreatine
- n-phosphocreatine
- n-(phosphonoamidino)sarcosine
- n-(phosphonoamidino)sarcosine
- n-phosphorocreatine
- n-phosphorylcreatine
- n-phosphorylcreatine
- n-phosphorylcreatine
- phosphocreatine
- phosphocreatine
- phosphocreatine
- phosphocreatine
- phosphocreatine
- phosphocreatine
- phosphocreatine
- phosphocreatine sodium tetrahydrate
- phosphorylcreatine
- phosphorylcreatine
- phosphorylcreatine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06503016 | Phase 3 | Oct 8, 2024 | Vita-Salute University of Milano. Italy |
| NCT05431413 | Phase 2 | Jul 7, 2020 | Southern Medical University |
| NCT03138681 | Phase 2 | May 3, 2017 | Southern Medical University |
| NCT02757443 | Phase 3 | Jun 1, 2016 | Moscow State University, Novosibirsk Research Institute of Circulation Pathology |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Southern Medical University | Academic/Hospital | 2 | 2 | 1 | 2017 |
| Moscow State University | Academic/Hospital | 1 | 1 | 1 | 2016 |
| Novosibirsk Research Institute of Circulation Pathology | Academic/Hospital | 1 | 0 | 1 | 2016 |
| Vita-Salute University of Milano. Italy | Academic/Hospital | 1 | 1 | 1 | 2024 |
4 organizations
Page 1 / 1